87 results on '"Jebbink M"'
Search Results
52. Effect of intravenous fat on cholecystokinin secretion and gallbladder motility in man.
- Author
-
De Boer, S.Y., Masclee, A.A.M., Jebbink, M.C.W., Schipper, J., Jansen, J.B.M.J., Lamers, C.B.H.W., Masclee, A A, Jebbink, M C, Jansen, J B, and Lamers, C B
- Published
- 1992
- Full Text
- View/download PDF
53. Effect of Erythromycin on Gallbladder Emptying in Patients with Antrectomy or Truncal Vagotomy.
- Author
-
Masclee, A. A. M., Ledeboer, M. L., Gielkens, H. G., Van der Kleij, F. G. H., Jebbink, M. C. W., and Lamers, C. B. H. W.
- Subjects
ERYTHROMYCIN ,GALLBLADDER ,VAGOTOMY ,ANTIBACTERIAL agents ,BILIARY tract - Abstract
Objectives: Erythromycin, a motilin-like agent, stimulates gallbladder contraction in healthy control subjects. Because the action of erythromycin is cholinergic dependent and possibly related to premature phase III migrating motor complex activity in the antrum, we investigated the effect of erythromycin on gallbladder volume in six patients with truncal vagotomy without gastric resection and 14 patients with antrectomy (6 with Billroth I anastomosis, 8 with Billroth II anastomosis), and we compared the results obtained with those in eight healthy controls. In addition, the effect of meal ingestion on gallbladder volume was studied. Methods: Gallbladder volumes, measured with ultrasonography, were determined every 15 min for 180 min after erythromycin infusion (3 mg/kg i.v.), as well as 30 and 60 min after meal ingestion. Results: Basal gallbladder volumes were not significantly different among the four groups. Erythromycin induced a significant (p <0.01-0.05) gallbladder contraction of maximal 46 &plumsn; 6% in the controls, 49 &plumsn; 9% in the patients with truncal vagotomy, and 38 &plumsn; 7% in the patients with antrectomy and Billroth I anastomosis. In the patients with antrectomy and Billroth II anastomosis, no significant reduction in gallbladder volume after erythromycin was observed. Meal-induced gallbladder contraction was normal in all patients, including those with Billroth II anastomosis. Conclusions: These results indicate that neither the long vagus nerve nor the antrum is essential for erythromycin-induced effects on the gallbladder. Because no significant reduction in gallbladder volume in response to erythromycin was observed in the patients with antrectomy and Billroth II anastomosis, we suggest that duodenojejunal anatomical integrity is essential for erythromycin-induced gallbladder contraction. [ABSTRACT FROM AUTHOR]
- Published
- 1995
54. MA07.03 Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2ndLine Osimertinib Treatment
- Author
-
Van Der Wel, T., Jebbink, M., Boelens, M.c., Steinbusch, L., Buikhuisen, W., Theelen, W., Ruiter, G., Burgers, J., Baas, P., Smit, E., Van Den Broek, D., Monkhorst, K., and Langen, A.J. De
- Published
- 2021
- Full Text
- View/download PDF
55. Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
- Author
-
Hondelink, L.M., Jebbink, M., von der Thüsen, J.H., Cohen, Danielle, Dubbink, H.J., Paats, M., Dingemans, A.C., de Langen, A.J., Boelens, M.C., Smit, E.F., Postmus, P.E., van Wezel, T., and Monkhorst, K.
- Abstract
With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are currently lacking. Here, we provide our recommendations for optimal molecular diagnostics in the post-EGFR tyrosine kinase inhibitor (TKI) resistance setting.
- Published
- 2021
- Full Text
- View/download PDF
56. Do patients with systemic sclerosis have abnormal gallbladder function?
- Author
-
Posthuma, Ward F.M., Ledeboer, Michiel, Masclee, Ad A.M., Dijkmans, Ben A.C., Westendorp, Rudi G.J., Jebbink, Max C.W., Breedveld, Ferdi C., Lamers, Cornelis B.H.W., Posthuma, W F, Ledeboer, M, Masclee, A A, Dijkmans, B A, Westendorp, R G, Jebbink, M C, Breedveld, F C, and Lamers, C B
- Published
- 1997
- Full Text
- View/download PDF
57. Localization of Human Papillomavirus Type 16 DNA Using the Polymerase Chain Reaction in the Cervix Uteri of Women with Cervical Intraepithelial Neoplasia
- Author
-
Cornelissen, M. T. E., primary, van den Tweel, J. G., additional, Struyk, A. P. H. B., additional, Jebbink, M. F., additional, Briet, M., additional, van der Noordaa, J., additional, and Ter Schegget, J., additional
- Published
- 1989
- Full Text
- View/download PDF
58. Human coronavirus 229E encodes a single ORF4 protein between the spike and the envelope genes
- Author
-
Berkhout Ben, Franklin Sally, Minor Philip D, Zaaijer Hans L, Pyrc Krzysztof, Wilbrink Berry, Jebbink Maarten F, Dijkman Ronald, Thiel Volker, and van der Hoek Lia
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The genome of coronaviruses contains structural and non-structural genes, including several so-called accessory genes. All group 1b coronaviruses encode a single accessory protein between the spike and envelope genes, except for human coronavirus (HCoV) 229E. The prototype virus has a split gene, encoding the putative ORF4a and ORF4b proteins. To determine whether primary HCoV-229E isolates exhibit this unusual genome organization, we analyzed the ORF4a/b region of five current clinical isolates from The Netherlands and three early isolates collected at the Common Cold Unit (CCU) in Salisbury, UK. Results All Dutch isolates were identical in the ORF4a/b region at amino acid level. All CCU isolates are only 98% identical to the Dutch isolates at the nucleotide level, but more closely related to the prototype HCoV-229E (>98%). Remarkably, our analyses revealed that the laboratory adapted, prototype HCoV-229E has a 2-nucleotide deletion in the ORF4a/b region, whereas all clinical isolates carry a single ORF, 660 nt in size, encoding a single protein of 219 amino acids, which is a homologue of the ORF3 proteins encoded by HCoV-NL63 and PEDV. Conclusion Thus, the genome organization of the group 1b coronaviruses HCoV-NL63, PEDV and HCoV-229E is identical. It is possible that extensive culturing of the HCoV-229E laboratory strain resulted in truncation of ORF4. This may indicate that the protein is not essential in cell culture, but the highly conserved amino acid sequence of the ORF4 protein among clinical isolates suggests that the protein plays an important role in vivo.
- Published
- 2006
- Full Text
- View/download PDF
59. Genome structure and transcriptional regulation of human coronavirus NL63
- Author
-
Berkhout Ben, Jebbink Maarten F, Pyrc Krzysztof, and van der Hoek Lia
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Two human coronaviruses are known since the 1960s: HCoV-229E and HCoV-OC43. SARS-CoV was discovered in the early spring of 2003, followed by the identification of HCoV-NL63, the fourth member of the coronaviridae family that infects humans. In this study, we describe the genome structure and the transcription strategy of HCoV-NL63 by experimental analysis of the viral subgenomic mRNAs. Results The genome of HCoV-NL63 has the following gene order: 1a-1b-S-ORF3-E-M-N. The GC content of the HCoV-NL63 genome is extremely low (34%) compared to other coronaviruses, and we therefore performed additional analysis of the nucleotide composition. Overall, the RNA genome is very low in C and high in U, and this is also reflected in the codon usage. Inspection of the nucleotide composition along the genome indicates that the C-count increases significantly in the last one-third of the genome at the expense of U and G. We document the production of subgenomic (sg) mRNAs coding for the S, ORF3, E, M and N proteins. We did not detect any additional sg mRNA. Furthermore, we sequenced the 5' end of all sg mRNAs, confirming the presence of an identical leader sequence in each sg mRNA. Northern blot analysis indicated that the expression level among the sg mRNAs differs significantly, with the sg mRNA encoding nucleocapsid (N) being the most abundant. Conclusions The presented data give insight into the viral evolution and mutational patterns in coronaviral genome. Furthermore our data show that HCoV-NL63 employs the discontinuous replication strategy with generation of subgenomic mRNAs during the (-) strand synthesis. Because HCoV-NL63 has a low pathogenicity and is able to grow easily in cell culture, this virus can be a powerful tool to study SARS coronavirus pathogenesis.
- Published
- 2004
- Full Text
- View/download PDF
60. Gallbladder responses to modified sham feedings: effects of the composition of a meal
- Author
-
Witteman, B. J. M., Jebbink, M. C. W., Hopman, W. P. M., and Masclee, A. A. M.
- Published
- 1993
- Full Text
- View/download PDF
61. Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study.
- Author
-
van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, van den Broek D, Smit EF, de Langen AJ, and Brandsma D
- Abstract
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation positive (EGFRm+) NSCLC is challenging. We aimed to identify resistance mechanisms (RM) to osimertinib in cerebrospinal fluid (CSF) and plasma., Methods: EGFRm+ patients with new or progressive LM during osimertinib were enrolled. NGS Ampliseq was performed on DNA isolated from CSF. Patients were prescribed osimertinib dose escalation (DE, 160mg QD) following lumbar puncture. Clinical and radiological response was evaluated four weeks after osimertinib DE., Results: Twenty-eight patients were included. The driver mutation was identified in 93% of CSF samples (n=26). Seven (27%) harbored ≥1 RM. Twenty-five patients (89%) were prescribed osimertinib DE. Four weeks afterwards, symptoms improved in five patients, stabilized in nine and worsened in eleven patients. Twenty-one (84%) patients underwent MR imaging. Four showed radiological improvement, fourteen stabilization, and three worsening., Conclusions: In 27% of patients an RM was found in CSF ctDNA, none of which are targetable at time of writing, and clinical efficacy of osimertinib DE seems limited. There is much to gain in diagnostic as well as therapeutic strategies in EGFRm+ NSCLC LM., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
62. Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR -Mutated NSCLC.
- Author
-
Gulikers JL, Veerman GDM, Jebbink M, Kruithof PD, Steendam CMJ, Boosman RJ, Mathijssen RHJ, Tjan-Heijnen VCG, Driessen JHM, Dursun S, Smit EF, Dingemans AC, van Geel RMJM, Croes S, and Hendriks LEL
- Abstract
Introduction: Brain metastases (BM) are common in patients with advanced EGFR -mutated ( EGFR m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C
min,SS ) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib Cmin,SS and BM development or progression., Methods: A prospective multicenter cohort study, including patients receiving osimertinib for advanced EGFR m + NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib Cmin,SS (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group., Results: A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (<159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (>270.7 ng/mL) Cmin,SS subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6-49.0), 31% (95% CI:10.6-53.9), and 31% (95% CI:10.8-54.5) per Cmin,SS subgroup, respectively. After 20 months, this was 20% (95% CI:2.6-49.0), 52% (95% CI:23.8-74.2), and 57% (95% CI:24.9-79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within Cmin,SS subgroups., Conclusions: No relation was found between osimertinib Cmin,SS and BM development or progression in patients with advanced EGFR m + NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression., Competing Interests: Dr. Veerman reports receiving payment or honoraria for lectures from Eli Lilly (payed to the institute). Dr. Steendam reports receiving an unrestricted research grant from AstraZeneca (payed to the institute), payment or honoraria for lectures from Academic Pharmaceutical, supporting for attending meetings from Eli Lilly and Rochte and fullfilling unpaid roles at NVALT and CieBOD. Prof. dr. Mathijssen reports receiving grants of contracts for investigator initiated research from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche, Sanofi and Sevier (all payed to the institute). Prof. dr. Tjan-Heijnen reports receiving grants or contracts from Pfizer, Novartis, Eli Lilly, Gilead, Roche, AstraZeneca and Daiichi Sankyo (all payed to the institute), and receiving consulting fees from Eli Lilly, Novartis and AstraZeneca. Drs. Dursun reports receiving payment or honoraria a presentation at Novartis. Prof. dr. Smit reports receiving grants or contracts from AstraZeneca and Daiichi Sankyo (payed to the institute), receiving consulting fees from AstraZeneca, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Sanofi, Eli Lilly, Roche Genentech, Merck, Novartis, Pfizer, Takeda and Taiho (all payed to the institute), participation on a data safety monitoring board or advisory board from DSI and Taiho and receiving payment of honoraria for lectures from Boehringer-Ingelheim. Prof. dr. Dingemans reports receiving grants or contracts from Amgen, Dutch Cancer Society and HANART (all payed to the institute), receiving consulting fees from AMGEN, Bayer, Boehringer-Ingelheim, Sanofy, Roche, Janssen and AstraZeneca (all payed to the institute), and receiving payment or honoraria for lectures from Janssen, Pfizer, AstraZeneca, Eli Lilly and Takeda (all payed to the institute), participation on a data and safety monitoring board or advisory board from Takeda and Roche and is unpaid char at EORTC LCG. Dr. van Geel reports receiving grants or contracts from Academic Alliance Fund (payed to the institute). Dr. Hendriks reports receiving grants or contracts from Roche Genentech, AstraZeneca, Boehringer-Ingelheim, Takeda, Merck, Pfizer and Novartis (all payed to the institute), receiving payment or honoraria for lectures from MSD, Eli Lilly, Sanofi, GSK and High5oncology (all payed to the institute), and personal payments from Benecke, Medtalks, Medimix, VJOncology, participation on a data safety monitoring board or advisory board from BMS, Eli Lilly, Roche Genetech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer-Ingelheim, Amgen, Janssen and Anhearts (all payed to the institute), and interview sessions funded by Roche Genentech, Bayer and Eli Lilly (all payed to the institute). All other authors declare no conflict of interest., (© 2024 The Authors.)- Published
- 2024
- Full Text
- View/download PDF
63. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
- Author
-
Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, and Mathijssen RHJ
- Abstract
Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated ( EGFR m+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimertinib is a substrate of transporters ABCB1 and ABCG2 and metabolized by CYP3A4. We investigated relationships between single nucleotide polymorphisms (SNPs) ABCB1 3435C>T, ABCG2 421C>A and 34G>A, and CYP3A4∗22 and CNS treatment efficacy of osimertinib in EGFR m+ NSCLC patients., Methods: Patients who started treatment with osimertinib for EGFR m+ NSCLC between November 2014 and June 2021 were included in this retrospective observational multicentre cohort study. For patients with baseline CNS metastases, the primary endpoint was CNS progression-free survival (CNS-PFS; time from osimertinib start until CNS disease progression or death). For patients with no or unknown baseline CNS metastases, the primary endpoint was CNS disease-free survival (CNS-DFS; time from osimertinib start until occurrence of new CNS metastases). Relationships between SNPs and baseline characteristics with CNS-PFS and CNS-DFS were studied with competing-risks survival analysis. Secondary endpoints were relationships between SNPs and PFS, overall survival, severe toxicity, and osimertinib pharmacokinetics., Findings: From 572 included patients, 201 had baseline CNS metastases. No SNP was associated with CNS-PFS. Genotype ABCG2 34GA/AA and/or ABCB1 3435CC --present in 35% of patients-- was significantly associated with decreased CNS-DFS (hazard ratio 0.28; 95% CI 0.11-0.73; p = 0.009) in the multivariate analysis. This remained significant after applying a Bonferroni correction and internal validation through bootstrapping. ABCG2 421CA/AA was related to more severe toxicity (27.0% versus 16.5%; p = 0.010)., Interpretation: ABCG2 34G>A and ABCB1 3435C>T are predictors for developing new CNS metastases during osimertinib treatment, probably because of diminished drug levels in the CNS. ABCG2 421C>A was significantly related with the incidence of severe toxicity. Pre-emptive genotyping for these SNPs could individualize osimertinib therapy. Addition of ABCG2 inhibitors for patients without ABCG2 34G>A should be studied further, to prevent new CNS metastases during osimertinib treatment., Funding: No funding was received for this trial., Competing Interests: G.D.M.V. reports grants from Eli Lilly; outside the submitted work. A.C.D. reports grants from Boehringer-Ingelheim; outside the submitted work (paid to institution). R.H.J.M. reports an unrestricted grant from Boehringer-Ingelheim (paid to institution) and grants from Astellas, Bayer, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Sanofi, and Servier; outside the submitted work (paid to institution). L.E.L.H. has no relationship to disclose in relation to this manuscript. Outside of the current manuscript: research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda (all institution, Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD, Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati, Abbvie, Gilead. A.J.v.d.W. reports grants and advisory board from AstraZeneca, grants and advisory board from Boehringer-Ingelheim, advisory board from Janssen, advisory board from Novartis, grants and advisory board from Pfizer, grants and advisory board from Roche, grants and advisory board from Takeda, all outside the submitted work; all payment to the UMCG. N.S. provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Luszana. N. Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, Incyte, InteRNA, Janssen, Kinnate Biopharma, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute. E.F.S. has no relationship to disclose in relation to the manuscript. Outside the submitted work (all institutional): research grants from Astra Zeneca, MSD, BMS, Roche Genentech, advisory boards Astra Zeneca, BMS, Boehringer Ingelheim, Bayer, DSI, MSD, Takeda, Roche, Merck, Novartis, Amgen, Janssen. All other authors declare no competing interests., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
64. Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.
- Author
-
Boosman RJ, Jebbink M, Veldhuis WB, Groenland SL, van Veggel BAMH, Moeskops P, de Langen AJ, Beijnen JH, Smit EF, Huitema ADR, and Steeghs N
- Subjects
- Acrylamides, Aniline Compounds, ErbB Receptors genetics, Humans, Indoles, Mutation, Protein Kinase Inhibitors therapeutic use, Pyrimidines, Retrospective Studies, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Background: Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation positive non-small cell lung cancer (NSCLC). Clinical trials with osimertinib could not demonstrate an exposure-efficacy relationship, while a relationship between exposure and toxicity has been found. In this study, we report the exposure-response relationships of osimertinib in a real-life setting., Methods: A retrospective observational cohort study was performed, including patients receiving 40 - 80 mg osimertinib as ≥ 2 line therapy and from whom pharmacokinetic samples were collected during routine care. Trough plasma concentrations (C
min,pred ) were estimated and used as a measure of osimertinib exposure. A previously defined exploratory pharmacokinetic threshold of 166 µg/L was taken to explore the exposure-efficacy relationship., Results: A total of 145 patients and 513 osimertinib plasma concentration samples were included. Median progression free survival (PFS) was 13.3 (95% confidence interval (CI):10.3 - 19.1) months and 9.3 (95% CI: 7.2 - 11.1) months for patients with Cmin,pred < 166 µg/L and Cmin,pred ≥ 166 µg/L, respectively (p = 0.03). In the multivariate analysis, a Cmin,pred < 166 µg/L resulted in a non-statistically significant hazard ratio of 1.10 (95% CI: 0.60 - 2.01; p = 77). Presence of a EGFR driver-mutation other than the exon 19 del or L858R mutations, led to a shorter PFS with a hazard ratio of 2.89 (95% CI: 1.18 - 7.08; p = 0.02). No relationship between exposure and toxicity was observed (p = 0.91)., Conclusion: In our real-life cohort, no exposure-response relationship was observed for osimertinib in the current dosing scheme. The feasibility of a standard lower fixed dosing of osimertinib in clinical practice should be studied prospectively., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
65. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
- Author
-
Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, and Aerts JG
- Subjects
- Antimetabolites, Antineoplastic pharmacology, Antimetabolites, Antineoplastic therapeutic use, Cytokines metabolism, Deoxycytidine pharmacology, Deoxycytidine therapeutic use, Humans, Immunosuppressive Agents pharmacology, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism, Lymphocyte Activation drug effects, Lymphocyte Activation immunology, Mesothelioma diagnosis, Mesothelioma drug therapy, Mesothelioma mortality, Myeloid-Derived Suppressor Cells drug effects, Myeloid-Derived Suppressor Cells immunology, Myeloid-Derived Suppressor Cells metabolism, Prognosis, Treatment Outcome, Gemcitabine, Deoxycytidine analogs & derivatives, Immunomodulation drug effects, Mesothelioma immunology, Monitoring, Immunologic
- Abstract
Background: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significantly prolonged progression-free survival (PFS) compared to best supportive care (BSC) in malignant mesothelioma. Whether these effects are paralleled by changes in circulating immune cell subsets is currently unknown. These analyses could offer improved mechanistic insights into the effects of gemcitabine on the host and guide development of effective combination therapies in mesothelioma., Methods: We stained peripheral blood mononuclear cells (PBMCs) and myeloid-derived suppressor cells (MDSCs) at baseline and 3 weeks following start of gemcitabine or BSC treatment in a subgroup of mesothelioma patients included in the NVALT19-trial. In total, 24 paired samples including both MDSCs and PBMCs were included. We performed multicolour flow-cytometry to assess co-inhibitory and-stimulatory receptor- and cytokine expression and matched these parameters with PFS and OS., Findings: Gemcitabine treatment was significantly associated with an increased NK-cell- and decreased T-regulatory cell proliferation whereas the opposite occurred in control patients. Furthermore, myeloid-derived suppressor cells (MDSCs) frequencies were lower in gemcitabine-treated patients and this correlated with increased T-cell proliferation following treatment. Whereas gemcitabine variably altered co-inhibitory receptor expression, co-stimulatory molecules including ICOS, CD28 and HLA-DR were uniformly increased across CD4
+ T-helper, CD8+ T- and NK-cells. Although preliminary in nature, the increase in NK-cell proliferation and PD-1 expression in T cells following gemcitabine treatment was associated with improved PFS and OS., Interpretation: Gemcitabine treatment was associated with widespread effects on circulating immune cells of mesothelioma patients with responding patients displaying increased NK-cell and PD-1 + T-cell proliferation. These exploratory data provide a platform for future on treatment-biomarker development and novel combination treatment strategies., Competing Interests: Declaration of Interests JGA reports personal fees and non-financial support from MSD, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from amphera, personal fees from Eli-Lilly, personal fees from Takeda, personal fees from Bayer, personal fees from Roche, personal fees from Astra Zeneca, all outside the submitted work; In addition, JGA has a patent on allogenic tumour cell lysate licensed to amphora (EP2938354A1), a patent combination immunotherapy in cancer (pending), and a patent biomarker for immunotherapy (pending) . PB participated in advisory boards of MSD and BMS and AstraZeneca for which the Netherlands Cancer Institute received a reimbursement, outside the submitted work. PB participated in advisory boards of Takeda. PB received financial support for an investigator-initiated trial from MSD and BMS. RC participated in advisory boards of MSD and Roche and received a speaker fee from Roche, Pfizer and BMS, outside the submitted work. JAB reports reimbursement from BMS and F Hoffmann-La Roche for the Netherlands Cancer Institute, and financial support for an investigator-initiated trial from MSD, outside the submitted work. CJG, VN, JS, FD, BB, GB, MJ, LK, JM, LL, CW, MVG, HV, MKL and ML declare no competing interests., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
66. Euclidean Distance Analysis Enables Nucleotide Skew Analysis in Viral Genomes.
- Author
-
van Hemert F, Jebbink M, van der Ark A, Scholer F, and Berkhout B
- Subjects
- Algorithms, Animals, Coronavirus classification, Coronavirus genetics, HIV-1 classification, HIV-1 genetics, Humans, Likelihood Functions, Mathematical Concepts, Models, Genetic, Phylogeny, Picornaviridae classification, Picornaviridae genetics, Rubella virus classification, Rubella virus genetics, Base Composition, Genome, Viral, RNA, Viral genetics
- Abstract
Nucleotide skew analysis is a versatile method to study the nucleotide composition of RNA/DNA molecules, in particular to reveal characteristic sequence signatures. For instance, skew analysis of the nucleotide bias of several viral RNA genomes indicated that it is enriched in the unpaired, single-stranded genome regions, thus creating an even more striking virus-specific signature. The comparison of skew graphs for many virus isolates or families is difficult, time-consuming, and nonquantitative. Here, we present a procedure for a more simple identification of similarities and dissimilarities between nucleotide skew data of coronavirus, flavivirus, picornavirus, and HIV-1 RNA genomes. Window and step sizes were normalized to correct for differences in length of the viral genome. Cumulative skew data are converted into pairwise Euclidean distance matrices, which can be presented as neighbor-joining trees. We present skew value trees for the four virus families and show that closely related viruses are placed in small clusters. Importantly, the skew value trees are similar to the trees constructed by a "classical" model of evolutionary nucleotide substitution. Thus, we conclude that the simple calculation of Euclidean distances between nucleotide skew data allows an easy and quantitative comparison of characteristic sequence signatures of virus genomes. These results indicate that the Euclidean distance analysis of nucleotide skew data forms a nice addition to the virology toolbox.
- Published
- 2018
- Full Text
- View/download PDF
67. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures.
- Author
-
Pyrc K, Sims AC, Dijkman R, Jebbink M, Long C, Deming D, Donaldson E, Vabret A, Baric R, van der Hoek L, and Pickles R
- Subjects
- Cell Culture Techniques, Cells, Cultured, Coronavirus growth & development, Epithelial Cells cytology, HLA-C Antigens, Humans, Models, Biological, Respiratory System pathology, Virion, Virus Internalization, Virus Replication, Coronavirus physiology, Epithelial Cells virology, Respiratory System virology
- Abstract
Culturing newly identified human lung pathogens from clinical sample isolates can represent a daunting task, with problems ranging from low levels of pathogens to the presence of growth suppressive factors in the specimens, compounded by the lack of a suitable tissue culture system. However, it is critical to develop suitable in vitro platforms to isolate and characterize the replication kinetics and pathogenesis of recently identified human pathogens. HCoV-HKU1, a human coronavirus identified in a clinical sample from a patient with severe pneumonia, has been a major challenge for successful propagation on all immortalized cells tested to date. To determine if HCoV-HKU1 could replicate in in vitro models of human ciliated airway epithelial cell cultures (HAE) that recapitulate the morphology, biochemistry, and physiology of the human airway epithelium, the apical surfaces of HAE were inoculated with a clinical sample of HCoV-HKU1 (Cean1 strain). High virus yields were found for several days postinoculation and electron micrograph, Northern blot, and immunofluorescence data confirmed that HCoV-HKU1 replicated efficiently within ciliated cells, demonstrating that this cell type is infected by all human coronaviruses identified to date. Antiserum directed against human leukocyte antigen C (HLA-C) failed to attenuate HCoV-HKU1 infection and replication in HAE, suggesting that HLA-C is not required for HCoV-HKU1 infection of the human ciliated airway epithelium. We propose that the HAE model provides a ready platform for molecular studies and characterization of HCoV-HKU1 and in general serves as a robust technology for the recovery, amplification, adaptation, and characterization of novel coronaviruses and other respiratory viruses from clinical material.
- Published
- 2010
- Full Text
- View/download PDF
68. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
- Author
-
Lukashov VV, Huismans R, Jebbink MF, Danner SA, de Boer RJ, and Goudsmit J
- Subjects
- Amino Acid Sequence, Anti-HIV Agents pharmacology, Base Sequence, DNA, Viral, Drug Resistance, Microbial genetics, Evolution, Molecular, Genetic Heterogeneity, HIV Infections drug therapy, HIV Protease Inhibitors pharmacology, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, HIV-1 genetics, HIV-1 growth & development, Humans, Lamivudine pharmacology, Lamivudine therapeutic use, Molecular Sequence Data, Mutagenesis, Insertional, Phylogeny, Reverse Transcriptase Inhibitors pharmacology, Saquinavir pharmacology, Saquinavir therapeutic use, Stavudine pharmacology, Stavudine therapeutic use, Time Factors, Zidovudine pharmacology, Anti-HIV Agents therapeutic use, Drug Resistance, Multiple genetics, HIV Infections virology, HIV Reverse Transcriptase genetics, HIV-1 enzymology, Reverse Transcriptase Inhibitors therapeutic use, Zidovudine therapeutic use
- Abstract
We studied the intrahost evolution and dynamics of a multidrug-resistant HIV-1, which contains an insertion of two amino acids (aa) and several aa changes within the reverse transcriptase (RT) gene. From an individual receiving intermittent therapy, sequences of 231 full-length molecular clones of HIV-1 RT were obtained from serum-derived viruses at 12 consecutive time points over a period of 6 years, 17 to 20 clones per time point. In the 3.5-year period prior to the first course of therapy, only wild-type (wt) viruses were found. As soon as 6 months after the start of zidovudine (AZT) monotherapy, all viruses contained an insertion of two aa between positions 68 and 69 of the RT and aa changes at positions 67 and 215, a combination conferring resistance to multiple nucleoside analogs. After termination of therapy, the insertion mutants were rapidly and completely replaced by the wt viruses. In turn, the insertion mutants replaced the wt viruses after initiation of therapy with 3TC, d4T, and saquinavir. After termination of triple therapy, the wt viruses completely replaced the mutants within 1 month, which is markedly faster than has been observed earlier for the replacement of AZT-resistant viruses. Fast replacements of the mutant virus populations after termination of therapy indicate gross competitive disadvantage of the insertion mutant in the absence of therapy, which we estimated by using several models. The insertion mutants attained high virus loads, demonstrating that virus load cannot be used as a direct measure of virus fitness.
- Published
- 2001
- Full Text
- View/download PDF
69. Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus.
- Author
-
Berkhout B, Jebbink M, and Zsíros J
- Subjects
- Amino Acid Sequence, Cloning, Molecular, Endogenous Retroviruses physiology, Humans, Molecular Sequence Data, Open Reading Frames, RNA-Directed DNA Polymerase physiology, Recombination, Genetic, Ribonuclease H metabolism, Endogenous Retroviruses genetics, RNA-Directed DNA Polymerase genetics
- Abstract
Of the numerous endogenous retroviral elements that are present in the human genome, the abundant HERV-K family is distinct because several members are transcriptionally active and coding for biologically active proteins. A detailed phylogeny of the HERV-K family based on the partial sequence of the reverse transcriptase (RT) gene revealed a high incidence of an intact RT open reading frame within the HML-2 subgroup of HERV-K elements. In this study, we report the cloning of six full-length HML-2 RT genes, of which five contain an uninterrupted open reading frame. The RT enzymes were expressed as glutathione S-transferase fusion proteins in Escherichia coli, and several HERV-K RT enzymes demonstrated polymerase as well as RNase H activity. Several biochemical properties of the RT polymerase were analyzed, including the template requirements and optimal reaction conditions (temperature, type of divalent cation). Inspection of the nucleotide sequence of the HERV-K RT genes demonstrated a mosaic structure, suggesting that a high level of genetic recombination has occurred in this virus family, which is a hallmark of replication by means of reverse transcription. The selective pressure to maintain the RT coding potential is illustrated by the sequence of a particular HERV-K isolate that contains three 1-nucleotide deletions within a small RT segment, thus maintaining the open reading frame. These combined results may suggest that these endogenous RT enzymes still have a biological function. It is possible that the RT activity was involved in the spread of this major class of retroelements by retrotransposition, and in fact it cannot be excluded that this retrovirus group is still mobile. The endogenous RT activity may also have been involved in the shaping of the human genome, e.g., by formation of pseudogenes.
- Published
- 1999
- Full Text
- View/download PDF
70. Biased nucleotide composition of the genome of HERV-K related endogenous retroviruses and its evolutionary implications.
- Author
-
Zsíros J, Jebbink MF, Lukashov VV, Voûte PA, and Berkhout B
- Subjects
- Base Composition, Base Sequence, Computational Biology, Conserved Sequence, CpG Islands genetics, HIV Reverse Transcriptase genetics, HIV-1 genetics, Humans, Molecular Sequence Data, Mutation, Open Reading Frames genetics, Sequence Analysis, DNA, Endogenous Retroviruses chemistry, Endogenous Retroviruses genetics, Evolution, Molecular, Genome, Viral
- Abstract
The human genome contains a large number of sequences that belong to the HERV-K family of human endogenous retroviruses. Most of these elements are likely remnants of ancient infections by ancestral exogenous retroviruses. To obtain further insight into the evolutionary history and molecular mechanisms responsible for the diversity of the human HERV-K elements, we analyzed several aspects of their genome structure. The nucleotide composition of the HERV-K genome was found to be highly biased and asymmetric, with an abundance of the A nucleotide in the viral (+) strand. A similar trend has been reported for the genomes of several exogenous retroviruses, with different nucleotides as the preferred building block. Other genome characteristics that were reported previously for actively replicating retroviruses are also apparent for the endogenous HERV-K virus. In particular, we observed suppression of the dinucleotide CpG, which represents potential methylation sites, and a strong preference for synonymous substitutions within the open reading frame of the reverse transcriptase (RT) enzyme. Furthermore, the mutational spectrum of the HERV-K RT enzyme was evaluated by nucleotide sequence comparison of 34 available elements. Interestingly, this analysis revealed a striking similarity with the mutational pattern of the HIV-1 RT enzyme, with a preference for G-to-A and C-to-T transitions. It is proposed that the mutational bias of the HERV-K RT enzyme played a role in the shaping of this retroviral genome, which was actively replicating more than 30 million years ago. This effect can still be observed in the contemporary endogenous HERV-K elements.
- Published
- 1999
- Full Text
- View/download PDF
71. Identification of novel human endogenous retroviral sequences belonging to the HERV-K family.
- Author
-
Zsíros J, Jebbink MF, Voûte PA, and Berkhout B
- Subjects
- Amino Acid Sequence, Cell Line, Humans, Molecular Sequence Data, Phylogeny, RNA-Directed DNA Polymerase chemistry, RNA-Directed DNA Polymerase genetics, Reverse Transcriptase Polymerase Chain Reaction, Sequence Homology, Amino Acid, Tumor Cells, Cultured, Endogenous Retroviruses genetics
- Published
- 1998
- Full Text
- View/download PDF
72. Evolutionary relationships within a subgroup of HERV-K-related human endogenous retroviruses.
- Author
-
Zsíros J, Jebbink MF, Lukashov VV, Voûte PA, and Berkhout B
- Subjects
- Base Sequence, Child, DNA, Viral, Humans, Leukemia blood, Leukemia virology, Molecular Sequence Data, Phylogeny, Polymerase Chain Reaction, Retroviridae classification, Sequence Homology, Nucleic Acid, Evolution, Molecular, Retroviridae genetics
- Abstract
The prototype endogenous retrovirus HERV-K10 was identified in the human genome by its homology to the exogenous mouse mammary tumour virus. By analysis of a short 244 bp segment of the reverse transcriptase (RT) gene of other HERV-K10-like sequences, it has become clear that these elements represent an extended family consisting of multiple groups (the HML-1 to HML-6 subgroups). Some of these elements are transcriptionally active and contain an intact open reading frame for the RT protein, raising the possibility that this family is still expanding through retrotransposition. To better define the relationship of these endogenous retroviruses, we identified ten new members of the HML-2 subgroup. PCR was used to amplify reverse-transcribed RNA of a 595 bp region of the RT gene in a variety of human cell samples, including normal and leukaemic bone marrow and peripheral blood, placenta cells and a transformed T cell line. We provide an extensive phylogenetic analysis of the relationships for this cluster of HERV-K-related endogenous retroviral elements. Nucleotide diversity values for nonsynonymous versus synonymous codon positions indicate that moderately strong selection is or was operating on these retroviral RT gene segments. The evolution of this class of endogenous retroelements is discussed.
- Published
- 1998
- Full Text
- View/download PDF
73. Effect of antrectomy and truncal vagotomy on erythromycin induced pancreatic polypeptide secretion.
- Author
-
Masclee AA, Gielkens HG, Ledeboer ML, van der Kleij FG, Jebbink MC, and Lamers CB
- Subjects
- Adult, Aged, Analysis of Variance, Anastomosis, Surgical, Female, Gastrointestinal Motility drug effects, Humans, Male, Middle Aged, Pancreatic Polypeptide blood, Pyloric Antrum surgery, Reference Values, Erythromycin pharmacology, Gastrectomy, Pancreatic Polypeptide pharmacology, Vagotomy
- Abstract
Erythromycin, a motilin agonist, enhances gastrointestinal motility but also stimulates endogenous pancreatic polypeptide (PP) secretion. We investigated whether the effect of erythromycin on PP release is dependent on (1) prokinetic activity of erythromycin generated from the antrum and (2) the long vagus nerve since erythromycin acts via cholinergic neurons. Erythromycin induced PP secretion was determined in 14 patients with antrectomy (6 patients with Billroth I type anastomosis, 8 patients with Billroth II type anastomosis), in 6 patients with truncal vagotomy and pyloroplasty but without gastric resection and in 8 healthy controls. Plasma PP levels in response to erythromycin (3 mg/kg i.v.) were determined at regular intervals for 180 min. Erythromycin induced a significant increase in plasma PP in the control subjects from 22 +/- 4 pmol/l (basal) to 49 +/- 4 pmol/l at 10 min. In the patients with truncal vagotomy plasma PP secretion after erythromycin was significantly (P < 0.05) increased (peak increment vs. basal: 98 +/- 10 pmol/l vs. 27 +/- 2 pmol/l) and prolonged compared to controls. In the patients with antrectomy no significant increases in plasma PP over basal were observed after erythromycin infusion. It is concluded that erythromycin stimulates PP secretion in healthy controls. The PP response to erythromycin is exaggerated after truncal vagotomy but absent after antrectomy indicating that the antrum is essential for erythromycin induced PP secretion.
- Published
- 1995
- Full Text
- View/download PDF
74. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts.
- Author
-
Smits HL, van Gemen B, Schukkink R, van der Velden J, Tjong-A-Hung SP, Jebbink MF, and ter Schegget J
- Subjects
- Base Sequence, Cervix Uteri pathology, Cervix Uteri virology, DNA, Viral analysis, Female, Humans, Molecular Sequence Data, Papillomavirus E7 Proteins, Tumor Cells, Cultured, Nucleic Acid Amplification Techniques, Oncogene Proteins, Viral isolation & purification, Papillomaviridae genetics, RNA, Viral analysis, Repressor Proteins
- Abstract
Using a human papillomavirus type 16 (HPV-16) E6-E7 specific primer set in a nucleic acid sequence-based amplification (NASBA) reaction, detection of HPV-16 transcripts was accomplished in a single enzymatic reaction at 41 degrees C. The NASBA reaction product was visualized either by Northern bolt analysis with an HPV-16 E6-E7-specific 32P-labelled oligonucleotide probe or by a non-radioactive enzyme-linked gel assay (ELGA). In combination with a rapid nucleic acid extraction procedure this method appears to be very suitable for the sensitive and specific detection of HPV-16 transcripts on small amounts of HPV-16-expressing cells of various sources, including cervical smears.
- Published
- 1995
- Full Text
- View/download PDF
75. Nutrient-specific effects of modified sham feeding on pancreatic polypeptide release.
- Author
-
Witteman BJ, Edwards-Teunissen K, Hopman WP, Jebbink MC, Masclee AA, Lamers CB, and Jansen JB
- Subjects
- Adult, Aged, Cholinergic Fibers drug effects, Cholinergic Fibers physiology, Female, Humans, Male, Middle Aged, Pancreatic Polypeptide blood, Radioimmunoassay, Time Factors, Vagus Nerve drug effects, Vagus Nerve physiology, Dietary Carbohydrates pharmacology, Dietary Fats pharmacology, Dietary Proteins pharmacology, Pancreatic Polypeptide drug effects, Pancreatic Polypeptide metabolism
- Abstract
Objective: To study the effect of meal composition on pancreatic polypeptide release during modified sham feeding., Design: In random order and on separate occasions, isocaloric, isothermic, isoosmotic, homogenized meals (1050 kJ; 250 kcal) either rich in fat (walnuts; 64 g fat, 7 g protein, 15 g starch per 100 g), protein (codfish, 1 g fat, 23 g protein per 100 g) or carbohydrates (bananas; 22 g starch, 1 g protein per 100 g) were sham-fed for 30 min by tasting and spitting out the meal. The plasma pancreatic polypeptide response was monitored by radioimmunoassay at 10 min intervals from 20 min before to 120 min after modified sham feeding., Setting: Department of Gastroenterology and Hepatology of a University Hospital., Subjects: Seven healthy volunteers: 3 male, 4 female; age 45 (range 30-77) years., Results: Integrated plasma pancreatic polypeptide responses to modified sham feeding of codfish (1088 +/- 395 pM*120 min; P < 0.05) and walnuts (1200 +/- 542 pM*120 min) were distinctly higher (P < 0.05) than to modified sham feeding of bananas (-390 +/- 291 pM*120 min)., Conclusions: These results demonstrate that the pancreatic polypeptide response to modified sham feeding is dependent on the composition of the meal.
- Published
- 1994
76. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers.
- Author
-
Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, Jebbink MF, and Smits HL
- Subjects
- Base Sequence, Consensus Sequence, DNA Probes, DNA, Viral classification, Female, Humans, Molecular Sequence Data, Papillomaviridae classification, Papillomaviridae genetics, Polymerase Chain Reaction, Sensitivity and Specificity, Sequence Homology, Nucleic Acid, Cervix Uteri microbiology, DNA, Viral isolation & purification, Papillomaviridae isolation & purification, Warts microbiology
- Abstract
Two sets of consensus PCR primers consisting of a common 3' primer CP-I and two 5'-primers, CP-IIG (primer set A) and CP-IIS (primer set B), in the E1 open reading frame of the human papillomavirus (HPV) genome are presented. These two primer sets enabled the detection of a 188 base pair (bp) fragment of HPV 1, 2, 3, 4, 5, 6b, 7, 8, 9, 10a, 11, 12, 14a, 16, 17, 18, 19, 20, 21, 22, 24, 25, 31, 33, 36, 37, 38, 39 and 46. HPV types 15, 23, 49 and 50 were poorly amplified and HPV type 41 was not amplified. The method is suitable for the detection of HPV DNA sequences in clinical samples of both cervical and cutaneous lesions.
- Published
- 1993
- Full Text
- View/download PDF
77. Effect of loxiglumide on basal and gastrin- and bombesin-stimulated gastric acid and serum gastrin levels.
- Author
-
Jebbink MC, Lamers CB, Mooy DM, Rovati LC, and Jansen JB
- Subjects
- Adult, Female, Gastrins pharmacology, Humans, Male, Proglumide pharmacology, Bombesin pharmacology, Cholecystokinin antagonists & inhibitors, Gastric Acid metabolism, Gastrins blood, Proglumide analogs & derivatives, Receptors, Cholecystokinin drug effects
- Abstract
The effect of the specific cholecystokinin-receptor antagonist loxiglumide on basal and bombesin-, and gastrin 17-I-stimulated gastric acid secretion and serum gastrin levels was studied in 12 healthy subjects. Loxiglumide (10 mg.kg-1.h-1) significantly augmented basal gastric acid output from 1.8 +/- 0.3 to 3.9 +/- 0.6 mmol H+/h (P less than 0.005) but did not significantly influence integrated basal serum gastrin concentrations (2 +/- 21 vs. 32 +/- 21 pmol L-1.h-1). Both gastric acid secretion and integrated serum gastrin concentrations stimulated by bombesin infusion (92.6 pmol.kg-1.h-1) were significantly augmented by loxiglumide [from 4.0 +/- 0.3 to 10.0 +/- 1.3 mmol H+/h (P less than 0.005) and from 1251 +/- 93 to 2558 +/- 206 pmol.L-1.h-1 (P less than 0.005), respectively]. Gastric acid output and serum gastrin concentrations during infusion of 5 pmol.kg-1.h-1 of synthetic human gastrin 17-I (9.6 +/- 2.9 mmol H+/h and 1045 +/- 177 pmol.L-1.h-1) and during infusion of 15 pmol.kg-1.h-1 of gastrin 17-I (14.5 +/- 3.1 mmol H+/h and 2412 +/- 312 pmol.L-1.h-1) were not significantly influenced by loxiglumide (10.3 +/- 2.3 mmol H+/h and 1291 +/- 257 pmol.L-1.h-1 for the 5-pmol.kg-1.h-1 gastrin 17-I infusion dose with loxiglumide and 13.6 +/- 3.4 mmol H+/h and 2611 +/- 305 pmol.L-1.h-1 for the 15-pmol.kg-1.h-1 gastrin 17-I infusion dose with loxiglumide). These data indicate that endogenous cholecystokinin inhibits gastric acid secretion under basal conditions and gastrin release and gastric acid secretion during infusion of bombesin in humans and suggest that the augmented effect of loxiglumide on bombesin-stimulated gastric acid secretion may be explained largely by enhanced gastrin release.
- Published
- 1992
- Full Text
- View/download PDF
78. Effect of loxiglumide and atropine on erythromycin-induced reduction in gallbladder volume in human subjects.
- Author
-
Jebbink MC, Masclee AA, van der Kleij FG, Schipper J, Rovati LC, Jansen JB, and Lamers CB
- Subjects
- Adult, Cholecystokinin antagonists & inhibitors, Cholecystokinin blood, Female, Gallbladder diagnostic imaging, Humans, Male, Pancreatic Polypeptide blood, Proglumide pharmacology, Pulse drug effects, Ultrasonography, Atropine pharmacology, Erythromycin pharmacology, Gallbladder drug effects, Proglumide analogs & derivatives
- Abstract
This study was undertaken to investigate the effect of erythromycin, a motilin agonist with prokinetic activity, on fasting gallbladder volume. To evaluate the mechanism of action of erythromycin on gallbladder motility, erythromycin (3.5 mg/kg.20 min, intravenously) was infused on three separate occasions: during cholinergic blockage with atropine (0.005 mg/kg.hr), during cholecystokinin receptor blockade with loxiglumide (10 mg/kg.hr) and during saline solution infusion (control). Atropine, loxiglumide and saline solution infusions were started 3 hr before administration of erythromycin and were continued for 3 hr thereafter. Gallbladder volumes (measured by ultrasonography), plasma cholecystokinin levels (radioimmunoassay) and plasma pancreatic polypeptide levels (radioimmunoassay) were determined at regular intervals for 6 hr in six healthy volunteers. During the 3-hr infusion before administration of erythromycin, both loxiglumide and atropine significantly increased gallbladder volumes--from 18 +/- 2 to 37 +/- 3 cm3 (p less than 0.05) and from 17 +/- 3 to 24 +/- 2 cm3 (p less than 0.05), respectively--whereas saline solution did not significantly affect gallbladder volume. During control saline solution infusion, erythromycin induced prolonged gallbladder contraction that was significant (p less than 0.05) between 60 and 180 min and reached a maximum of 45% +/- 8% at 150 min. Plasma cholecystokinin levels were not affected by erythromycin. Erythromycin induced a significant (p less than 0.05) increase in plasma pancreatic polypeptide levels, from 12 +/- 1 pmol/L to 34 +/- 3 pmol/L. Loxiglumide did not prevent the erythromycin-induced reduction in gallbladder volume. Atropine markedly reduced the effect of erythromycin, causing slight but significant (p less than 0.05) gallbladder volume reductions (18% +/- 4%) between 150 and 180 min.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
79. Gallbladder disease in cystic fibrosis.
- Author
-
Jebbink MC, Heijerman HG, Masclee AA, and Lamers CB
- Subjects
- Cholecystectomy, Gallbladder Diseases diagnosis, Gallbladder Diseases therapy, Humans, Cystic Fibrosis complications, Gallbladder Diseases etiology
- Abstract
Among the various gastrointestinal manifestations observed in patients with cystic fibrosis (CF), gallbladder abnormalities occur frequently. These include a high prevalence of nonfunctioning gallbladders (30%), micro-gallbladders (8-30%), and gallstones (4-30%). The underlying pathophysiology for this increased prevalence in patients with CF is not completely understood, due to contradictory findings. These findings concern: (1) abnormalities in bile acid metabolism resulting in bile that is supersaturated with cholesterol, (2) an impaired nucleation time, and (3) biliary stasis, due to bile duct abnormalities and/or impaired gallbladder motility. The diagnosis of gallbladder disease in CF may be obscured by other common gastrointestinal complications, resulting in a long delay between onset of symptoms and the diagnosis. Cholecystectomy in CF is the treatment of choice, provided they are carefully managed in the pre- and perioperative period. The operative morbidity and mortality, even with intensive management of pulmonary disease, amounted to 10% and 5%, respectively. Therefore, alternative options, like laparoscopic cholecystectomy are of interest and require further investigation, especially for CF patients with severe pulmonary disease.
- Published
- 1992
80. Evidence against autocrine feedback regulation of cholecystokinin secretion in man.
- Author
-
Jebbink MC, Jansen JB, Mooy DM, Schouten CM, and Lamers CB
- Subjects
- Adult, Cholecystokinin blood, Cholecystokinin pharmacology, Feedback physiology, Humans, Infusions, Intravenous, Radioimmunoassay, Cholecystokinin metabolism, Eating physiology
- Abstract
To determine whether exogenous cholecystokinin (CCK) inhibits endogenous CCK release, cholecystokinin-8S (CCK-8S) was infused intravenously during continuous intraduodenal stimulation of endogenous CCK by a meal. CCK was measured in plasma by 2 region-specific radioimmunoassays employing antibodies T204 and 1703. AB T204 binds to carboxy-terminal CCK peptides containing the sulphated tyrosyl region, including CCK-8S, and AB 1703 to carboxy-terminal CCK peptides containing at least 14 amino acid residues. Meal-stimulated plasma CCK concentrations remained elevated during the entire infusion period. CCK-8S infusion further increased meal-stimulated plasma CCK concentrations, when measured with AB T204, while meal-stimulated plasma CCK concentrations were not suppressed by CCK-8S infusion, when measured with AB 1703. It is concluded that meal-stimulated endogenous CCK release is not affected by the effects of intravenously administered CCK-8S. These data suggest that autocrine feedback regulation of CCK release is not operative in man.
- Published
- 1992
- Full Text
- View/download PDF
81. Detection of human papillomavirus types by the polymerase chain reaction and the differentiation between high-risk and low-risk cervical lesions.
- Author
-
Cornelissen MT, Bots T, Briët MA, Jebbink MF, Struyk AP, van den Tweel JG, Greer CE, Smits HL, and ter Schegget J
- Subjects
- Biopsy, Cervix Uteri microbiology, DNA, Viral analysis, Diagnosis, Differential, Female, Humans, Papillomaviridae chemistry, Polymerase Chain Reaction, Risk Factors, Tumor Virus Infections pathology, Uterine Cervical Neoplasms pathology, Cervix Uteri pathology, Tumor Virus Infections diagnosis, Uterine Cervical Neoplasms diagnosis
- Abstract
By means of a consensus polymerase chain reaction (PCR) method, the prevalence of HPV types was determined in cervical biopsies from 137 women referred to the gynecological outpatient clinic for colposcopy because of an abnormal cervical smear. The prevalence of HPV was 80.3%. There was a statistically highly significant rise in the prevalence of the oncogenic HPV types (16, 18, 31, 33) with increasing severity of cervical intraepithelial neoplasia (CIN I to III), indicating a role for these HPV types in the pathogenesis of cervical cancer. The prevalence of other HPV types decreased significantly with the severity of the lesion, suggesting that these HPV types play a less significant role in this process. These data indicate that HPV typing with PCR may be a valuable tool for distinguishing between high-risk and low-risk cervical lesions. Furthermore, our results suggest that the detection of HPV types by consensus PCR in the cervix of patients with an abnormal smear but without histologically detectable CIN is a useful tool for predicting which of these patients will eventually develop CIN. Finally, a relatively low percentage (3%) of HPV double infections is reported in this study.
- Published
- 1992
- Full Text
- View/download PDF
82. Human papillomavirus type 16 transcripts expressed from viral-cellular junctions and full-length viral copies in CaSki cells and in a cervical carcinoma.
- Author
-
Smits HL, Cornelissen MT, Jebbink MF, van den Tweel JG, Struyk AP, Briët M, and ter Schegget J
- Subjects
- Base Sequence, Carcinoma genetics, Cell Line, Female, Genes, Viral, Humans, Molecular Sequence Data, Oligonucleotides chemistry, Polymerase Chain Reaction, Promoter Regions, Genetic, RNA Splicing, RNA, Messenger genetics, Uterine Cervical Neoplasms genetics, Viral Structural Proteins genetics, Carcinoma microbiology, Gene Expression Regulation, Viral, Papillomaviridae genetics, RNA, Viral genetics, Uterine Cervical Neoplasms microbiology
- Abstract
We have mapped using the RNA PCR the viral-cellular junctions of HPV16 viral-cellular cotranscripts expressed in CaSki cells and a cervical carcinoma to nt 3728 and 881, respectively. Both junctions were located within the E1-E2 region. Examination of the cellular sequences of the cotranscripts showed the presence of a polyadenylation signal in each of the transcripts. In CaSki cells and in the cervical carcinoma transcripts derived from the full-length early region including the E2 transcript were also detected. Our results suggest that the utilization of a cellular polyadenylation site could be important in the development of cancer by HPV.
- Published
- 1991
- Full Text
- View/download PDF
83. Effect of the specific cholecystokinin-receptor antagonist loxiglumide on bombesin stimulated pancreatic enzyme secretion in man.
- Author
-
Jebbink MC, Jansen JB, Mooy DM, Rovati LC, and Lamers CB
- Subjects
- Adult, Amylases metabolism, Bilirubin metabolism, Duodenum drug effects, Duodenum enzymology, Female, Humans, Male, Pancreas drug effects, Proglumide pharmacology, Bombesin pharmacology, Cholecystokinin blood, Pancreas enzymology, Proglumide analogs & derivatives, Receptors, Cholecystokinin drug effects
- Abstract
We have investigated the effects of the specific cholecystokinin (CCK) receptor antagonist loxiglumide on basal and bombesin stimulated pancreatic enzyme secretion, bilirubin output and plasma CCK release in six healthy subjects. The data were compared with those obtained in control experiments where saline was infused instead of loxiglumide. Basal amylase output (4.7 +/- 0.8 kU/45 min), trypsin output (2.9 +/- 0.8 kU/45 min) and bilirubin output (7.7 +/- 2.8 mmol/45 min) gradually declined during infusion of loxiglumide to values of 1.3 +/- 0.3 kU/45 min, 0.5 +/- 0.1 kU/45 min and 0.4 +/- 0.0 mmol/45 min, respectively, reaching statistical significance (P less than 0.05) in the 30 to 45-min period after the start of the loxiglumide infusion. In the control experiments saline infusion failed to influence basal amylase, trypsin and bilirubin output, while bombesin stimulated amylase output from 4.7 +/- 0.8 kU/45 min to 25.1 +/- 5.1 kU/45 min (P less than 0.05), trypsin output from 2.9 +/- 0.8 kU/45 min to 11.6 +/- 2.0 kU/45 min (P less than 0.05) and bilirubin output from 7.7 +/- 2.8 mmol/45 min to 68.0 +/- 16.0 mmol/45 min (P less than 0.05). Loxiglumide failed to significantly influence bombesin stimulated amylase output (36.7 +/- 9.0 kU/45 min) and trypsin output (8.3 +/- 2.9 kU/45 min), but almost abolished bilirubin output (9.7 +/- 3.6 mmol/45 min) (P less than 0.05). Basal plasma CCK (2.4 +/- 0.1 pM) was not significantly influenced by loxiglumide (2.4 +/- 0.2 pM).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
- Full Text
- View/download PDF
84. Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.
- Author
-
Jebbink MC, Jansen JB, Masclee AA, and Lamers CB
- Subjects
- Adult, Cholecystokinin antagonists & inhibitors, Cholecystokinin pharmacokinetics, Female, Half-Life, Humans, Male, Proglumide pharmacology, Cholecystokinin blood, Glutamine analogs & derivatives, Proglumide analogs & derivatives
- Abstract
Saline or loxiglumide (2.5 mg kg-1 in 10 min, followed by 5 mg kg-1 h-1 for 200 min) was administered intravenously in random order to six healthy subjects. After 60 min cholecystokinin (CCK-33) was infused (0.5 i.d.u. kg-1 h-1 for 1 h then 1.0 i.d.u. kg-1 h-1 for 1 h). Loxiglumide did not change basal levels of CCK and did not augment plasma CCK-immunoreactivity during CCK-33 infusion. After cessation of the CCK-infusion, plasma CCK concentrations decreased rapidly to basal values within 12 min, and the elimination half-life during loxiglumide infusion (4.8 +/- 0.8 min) was not significantly different from that during saline infusion (4.2 +/- 1.0 min). These results suggest that loxiglumide does not interfere with the distribution and metabolism of CCK.
- Published
- 1990
- Full Text
- View/download PDF
85. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA.
- Author
-
Smits PH, Smits HL, Jebbink MF, and ter Schegget J
- Subjects
- Cells, Cultured, Fibroblasts, Humans, Mutation, RNA, Viral analysis, Transfection, Chromosomes, Human, Pair 11 physiology, DNA, Viral metabolism, Enhancer Elements, Genetic, Papillomaviridae genetics, Promoter Regions, Genetic, Transformation, Genetic
- Abstract
Loci on the short arm of chromosome 11 between 11p11 and 11p15 likely are involved directly or indirectly in the regulation of the HPV-16 enhancer-promoter strength and this may contribute to the control of the level of viral early gene expression. Transient expression assays have shown that the HPV-16 enhancer-promoter functions much stronger in fibroblasts in which this region of chromosome 11 (del-11 cells) is deleted than in normal diploid human embryonic fibroblasts. The differential regulation of the HPV-16 long control region may be due either to the presence or activity of a cellular transcription factor which up-regulates HPV-16 early gene expression in del-11 cells or to a factor which down-regulates expression in diploid cells. Since the HPV-16 enhancer containing fragment (nt 7003 to nt 57) in combination with the SV40 promoter functions equally well in del-11 cells as in diploid cells a target of this factor likely is located in the putative HPV-16 early promoter region. The relative resistance of diploid human embryonic fibroblasts to HPV-16 induced transformation could be explained by the inactivity of the HPV-16 early promoter as these cells could be transformed by HPV-16 DNA constructs in which the early gene expression was driven from a heterologous enhancer-promoter. These results may indicate that loci on the short arm could suppress HPV-16-induced transformation by down-regulating the activity of the viral early promoter.
- Published
- 1990
- Full Text
- View/download PDF
86. Effect of pancreatic enzyme supplementation on postprandial plasma cholecystokinin secretion in patients with pancreatic insufficiency.
- Author
-
Jansen JB, Jebbink MC, Mulders HJ, and Lamers CB
- Subjects
- Adult, Bombesin pharmacology, Celiac Disease complications, Cholecystokinin metabolism, Eating, Exocrine Pancreatic Insufficiency complications, Exocrine Pancreatic Insufficiency drug therapy, Exocrine Pancreatic Insufficiency physiopathology, Female, Humans, Kinetics, Male, Middle Aged, Pancreatitis blood, Pancreatitis drug therapy, Pancreatitis physiopathology, Cholecystokinin blood, Exocrine Pancreatic Insufficiency blood, Pancreas enzymology, Pancreatin therapeutic use
- Abstract
To test the hypothesis, based on studies in healthy man and dog, that patients with impaired digestion due to severe pancreatic insufficiency have impaired postprandial cholecystokinin (CCK) secretion that can be improved by the addition of pancreatic enzymes, we have studied plasma CCK responses to a test meal with and without addition of pancreatic enzymes in 10 patients with pancreatic insufficiency and steatorrhea, in 8 patients with chronic pancreatitis without steatorrhea, and in 6 healthy subjects. The patients with steatorrhea had a significantly (P less than 0.001) lower integrated plasma CCK response to the meal (177 +/- 23 pM.150 min) than the healthy subjects (468 +/- 41 pM.150 min), while patients with chronic pancreatitis without steatorrhea had an intermediate integrated postprandial CCK secretion (327 +/- 101 pM.150 min). Addition of pancreatic enzymes to the meal significantly augmented the integrated CCK response in both the patients with steatorrhea to 483 +/- 72 pM.150 min (P less than 0.01) and in those without steatorrhea to 480 +/- 85 pM.150 min (P less than 0.05). These values were not significantly different from those in the healthy subjects (521 +/- 86 pM.150 min). Integrated CCK secretion in the three groups during bombesin infusion was similar (patients with steatorrhea 134 +/- 23 pM.20 min, patients without steatorrhea 131 +/- 33 pM.20 min, and healthy subjects 146 +/- 28 pM.20 min), indicating a normal capacity to secrete CCK in response to a humoral stimulus. These data are in agreement with the suggestions from previous studies that digestion of nutrients by pancreatic enzymes plays an important role in the regulation of plasma CCK secretion after feeding.
- Published
- 1989
- Full Text
- View/download PDF
87. The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man.
- Author
-
Douglas BR, Jebbink MC, Tjon a Tham RT, Jansen JB, and Lamers CB
- Subjects
- Adult, Female, Gallbladder anatomy & histology, Gallbladder drug effects, Humans, Male, Muscle Contraction drug effects, Proglumide pharmacology, Time Factors, Bombesin pharmacology, Cholecystokinin antagonists & inhibitors, Gallbladder physiology, Muscle, Smooth drug effects
- Abstract
This study was undertaken in 5 normal subjects to determine the role of cholecystokinin (CCK) in the regulation of basal gallbladder volume and gallbladder contraction stimulated by infusion of bombesin. Administration of the CCK-receptor antagonist, loxiglumide (CR-1505), led to doubling of the gallbladder volume (increase 104 +/- 26%; P less than 0.05) and reduced the bombesin-stimulated gallbladder contraction from 69 +/- 17 to 19 +/- 17% (P less than 0.05). The findings provide evidence suggesting that CCK plays an important role in the regulation of basal gallbladder tone and in mediating the gallbladder contraction induced by the administration of bombesin.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.